Sotera Health Company (SHC) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses.
Is Sotera Health Company stock overvalued or undervalued in 2026?
As of October 4, 2026, Sotera Health Company (SHC) trades at 32.4× earnings (P/E), against a median of 27.5× across the 157 pharma companies above $2bn in Kaplio's universe. Kaplio's verdict: fairly priced. At its sector median (27.5×) $16 (-15 %).
Kaplio overview: Sotera Health Company
Market cap $5B · 52 weeks $13 – $20 (5 % below the high) · P/E 32.4× · 2027 expected P/E 17.3× · Dividend none · Next earnings November 3, 2026 · expected EPS $0.27 · Price as of Oct 4 · accounts published Aug 6.
- Valuation: P/E 32.4× (fairly priced).
- Business: ROIC 9 % (fair).
- Balance sheet: Net debt/EBITDA 4.4× (fragile).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (27.5×) $16 (-15 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 1 of 5 pass
- R&D / Revenue 0.0 %, fails.
- Gross margin 55.5 %, fails.
- ROIC 8.8 %, fails.
- Net debt / EBITDA 4.4×, fails.
- FCF / Net Income 191.4 %, passes.
Against its peers (reference peers) — Sotera Health Company: P/E 32.4×; EV/EBITDA 13.3×; ROIC 8.8 %; $5.3B. Merit Medical Systems, Inc. (P/E 40.6×; EV/EBITDA 17.1×; ROIC 5.6 %; $5.1B), Bausch + Lomb Corporation (P/E —; EV/EBITDA 14.7×; ROIC 3.2 %; $6.1B), Alkermes plc (P/E 106×; EV/EBITDA 37.8×; ROIC 2.1 %; $6.7B).
Profitability
| Return on Equity | 26.75% |
| Return on Invested Capital | 8.80% |
| Return on Assets | 4.94% |
| Gross Margin | 54.72% |
| Operating Margin | 36.24% |
| Net Margin | 13.44% |
Financial Health
| Debt / Equity | 3.41 |
| Current Ratio | 2.80 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.79 |
Price Performance
| 1 month | -1.85% |
| 3 months | +6.18% |
| Year-to-date | +5.16% |
| 1 year | +14.36% |
| 3 years | +28.64% |
| 5 years | -28.35% |
Related companies: ALKS · BLCO · GKOS · MMSI · OPCH · OSCR
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of SHC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks